Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

Rybelsus (semaglutide) can cause side effects that range from mild to serious. More common side effects include constipation and diarrhea. If side effects from Rybelsus become difficult to ...

Rybelsus (semaglutide) is a prescription drug that’s used to manage blood sugar levels in people with type 2 diabetes. This drug can interact with other medications, such as levothyroxine ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its ...